Tony Hagen


PARP Inhibitors Continue to Show Promise in Ovarian Cancer

November 29, 2017

As PARP inhibitors continue to improve outcomes in patients with ovarian cancer, they may one day be moved into the frontline treatment setting, said Susana M. Campos, M.D., a gynecologic oncologist at Dana-Farber Cancer Institute and an assistant professor at Harvard Medical School.

New CAR T-Cell Therapy Comes With a Hefty Price Tag

August 31, 2017

The newly approved CAR T-cell therapy, Kymriah (tisagenlecleucel), is being put on the market with a price tag of $475,000 for a single infusion, which is within the range that oncologists predicted.

What’s Next for Drug Price Reforms in Oncology?

July 19, 2017

“If you locked everybody in a room for a week, I think we could come up with something that everybody would be comfortable with,” said Blase Polite, M.D., a co-author of the statement, and immediate past chair of ASCO’s government relations committee.

Expert Panel Agrees: Drug Price Reform Is Much Needed

June 19, 2017

Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.

A Cancer Foundation Grows From a Sentiment That Takes Root

March 07, 2016

Before losing her battle to ovarian cancer, Julie Paige McAvinn wanted to make sure other women were better educated about female cancers. Keeping his promise to his late wife, Peter McAvinn created the Julie Fund.

Building on the Success of Targeted Therapies in Thyroid Cancer

November 17, 2015

Nexavar and Lenvima have significantly altered the treatment paradigm for patients with advanced RAI-refractory differentiated thyroid cancer, with combination strategies hoping to further build upon this success.

An Rx for the System: Gaining Access to Investigational Drugs

February 26, 2015

Expanded access programs are run in conjunction with late-stage clinical trials so that promising investigational drugs can get into the hands of patients who stand a good chance of benefiting from them, and who have exhausted their other treatment options, including clinical trials.